WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 18 fonti

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

Raccontata dapbs.orgstatnews.combiopharmadive.comhealio.commedpagetoday.comnbcnews.comfiercebiotech.comindependent.co.uktheguardian.comdailymail.comcbsnews.comfortune.com+6 altre

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
pharmaceutical-technology.comStai leggendo15 h fa

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

originale
pbs.org3 g fa

Pancreatic cancer is deadly and difficult to treat. A new pill could change that

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Leggi questa versione → originale
biopharmadive.com2 g fa

‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

Leggi questa versione → originale
healio.com2 g fa

Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer

CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with…

Leggi questa versione → originale
cbsnews.com1 g fa

New drug nearly doubles survival rates in some pancreatic cancer patients, study says

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

Leggi questa versione → originale
eu.usatoday.com21 h fa

Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

Leggi questa versione → originale

Timeline cronologica

  1. sabato 30 maggio 2026·pbs.org

    Pancreatic cancer is deadly and difficult to treat. A new pill could change that

    The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

  2. sabato 30 maggio 2026·statnews.com

    Revolution Medicines starts shipping experimental pancreatic cancer drug

    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

  3. domenica 31 maggio 2026·biopharmadive.com

    ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer

    Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

  4. domenica 31 maggio 2026·healio.com

    Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer

    CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…

  5. domenica 31 maggio 2026·medpagetoday.com

    'Grand Slam' in Pancreatic Cancer: Novel Pill Doubles Survival

    RASolute 302 findings herald a new standard of care in previously treated patients

  6. domenica 31 maggio 2026·nbcnews.com

    After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses

    The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

  7. domenica 31 maggio 2026·fiercebiotech.com

    ASCO: Revolution Medicines confident in RAS leadership as rivals square up

    This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data…

  8. domenica 31 maggio 2026·independent.co.uk

    Daily pill almost doubles survival time for pancreatic cancer patients in new trial

    Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease

  9. domenica 31 maggio 2026·theguardian.com

    Daily pill can double survival time for world’s deadliest cancer, trial shows

    Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

  10. domenica 31 maggio 2026·dailymail.com

    New drug gives extra months of life to pancreatic cancer patients

    Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.

  11. domenica 31 maggio 2026·independent.co.uk

    Experimental pill promises new hope for deadly pancreatic cancer

    New research shows a novel pill is helping people with advanced pancreatic cancer live longer

  12. domenica 31 maggio 2026·independent.co.uk

    Pancreatic cancer breakthrough as pill almost doubles survival time for patients

    Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

  13. domenica 31 maggio 2026·cbsnews.com

    New drug nearly doubles survival rates in some pancreatic cancer patients, study says

    New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

  14. domenica 31 maggio 2026·fortune.com

    Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. 'I actually started crying' | Fortune

    The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for…

  15. domenica 31 maggio 2026·cnn.com

    Experimental pill promises new hope for deadly pancreatic cancer | CNN

    A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types…

  16. domenica 31 maggio 2026·dailysabah.com

    Experimental pill offers breakthrough hope in pancreatic cancer fight

    An experimental drug for advanced pancreatic cancer significantly extended survival in a major clinical trial, offering fresh hope for improved treatment...

  17. domenica 31 maggio 2026·inews.co.uk

    Why this new pill for a deadly cancer has doctors excited

    The results of a clinical trial of a new drug could signal a breakthrough in treating pancreatic cancer

  18. domenica 31 maggio 2026·calabria7.news

    Tumore al pancreas, svolta dalla ricerca: il farmaco daraxonrasib raddoppia la sopravvivenza (Calabria 7)

    Un nuovo studio clinico sta attirando grande attenzione nella comunità scientifica internazionale per i risultati ottenuti nel trattamento del tumore al

  19. lunedì 1 giugno 2026·nature.com

    Landmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatments

    Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

  20. lunedì 1 giugno 2026·benzinga.com

    Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits

    Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for both patients and investors.